Skip to content

Study · Animal study (in vivo) · rat · 1992

4 results

[Influence of delta-sleep-inducing peptide on the activity of proteolytic enzymes in the rat brain under hypokinesia].

Mendzheritskiĭ AM, Lysenko AV, Mikhaleva II

Ukrainskii biokhimicheskii zhurnal (1978)1 Sept 1992Cited by 1 (Europe PMC)

PMID1462368 (opens in a new tab)PepBankPUB-01462368
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In intact rats, a single dose of DSIP increased neutral proteinase activity in brain and blood serum.

    In plain wordsIn rats, one dose of DSIP raised the activity of neutral proteinase enzymes in brain and blood.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    IncreaseNeutral proteinase activity in brain and blood serum (intact animals)
    Study

    ratn: not reported in source

    Outcome group
    Metabolic pathways and metabolomics · Nervous system and cognition
    Studied dose
    12 micrograms/100 gAs given in this study (rat).

    Source sentences

    Summary
    Single administration of the delta-sleep-inducing peptide (DSIP) in a dose of 12 micrograms/100 g to intact animals makes the activity of neutral proteinases and cathepsin D higher in the rat brain and blood serum.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In intact rats, a single dose of DSIP increased cathepsin D activity in brain and blood serum.

    In plain wordsIn rats, one dose of DSIP raised the activity of the enzyme cathepsin D in brain and blood.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    IncreaseCathepsin D activity in brain and blood serum (intact animals)
    Study

    ratn: not reported in source

    Outcome group
    Metabolic pathways and metabolomics · Nervous system and cognition
    Studied dose
    12 micrograms/100 gAs given in this study (rat).

    Source sentences

    Summary
    Single administration of the delta-sleep-inducing peptide (DSIP) in a dose of 12 micrograms/100 g to intact animals makes the activity of neutral proteinases and cathepsin D higher in the rat brain and blood serum.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats under 1-h hypokinesia, DSIP injection decreased the cathepsin D A/B ratio to the control level.

    In plain wordsIn rats under one hour of restricted movement, DSIP brought a cathepsin D measure back to the control level.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    DecreaseCathepsin D A/B ratio under 1-h hypokinesia
    Study

    ratn: not reported in source

    Outcome group
    Metabolic pathways and metabolomics · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Injection DSIP induces a decrease A/B of cathepsin D to the control level under 1-h hypokinesia condition and normalizes the neutral proteolytic activity under 6-h hypokinesia condition.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats under 6-h hypokinesia, DSIP injection normalized neutral proteolytic activity.

    In plain wordsIn rats under six hours of restricted movement, DSIP brought neutral protein-cutting enzyme activity back to normal.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    Not applicableNeutral proteolytic activity under 6-h hypokinesia
    Study

    ratn: not reported in source

    Outcome group
    Metabolic pathways and metabolomics · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    normalizes the neutral proteolytic activity under 6-h hypokinesia condition.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.